Pharmacodynamics and pharmacokinetics of DX-9065a in renal impairment.

被引：0
|
作者：
Depasse, F
Kunitada, S
Busson, J
Haque, N
Samama, MM
机构：
[1] LCL, Ivry, France
[2] Daiichi Pharmaceut Co Ltd, London, England
[3] Hop Hotel Dieu, Serv Hematol Biol, Paris, France
[4] Daiichi Pharmaceut Co Ltd, Tokyo, Japan
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4193
引用
收藏
页码：121B / 121B
页数：1
相关论文
共 50 条
  • [31] Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin
    Lefevre, G
    Duval, M
    Gauron, S
    Brookman, LJ
    Rolan, PE
    Morris, TM
    Piraino, AJ
    Morgan, JM
    Palmisano, M
    Close, P
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (01) : 50 - 59
  • [32] Pharmacokinetics and pharmacodynamics of evolocumab in patients with renal impairment
    Lee, E.
    Gibbs, J.
    Wasserman, S. M.
    Block, G.
    Emery, M. G.
    Abosaleem, B.
    Tracy, M.
    Gibbs, M.
    Somaratne, R.
    Kasichayanula, S.
    Hanafin, P.
    Egbuna, O.
    EUROPEAN HEART JOURNAL, 2016, 37 : 343 - 343
  • [33] DX-9065A, A NEW SYNTHETIC, POTENT ANTICOAGULANT AND SELECTIVE INHIBITOR FOR FACTOR-XA
    HARA, T
    YOKOYAMA, A
    ISHIHARA, H
    YOKOYAMA, Y
    NAGAHARA, T
    IWAMOTO, M
    THROMBOSIS AND HAEMOSTASIS, 1994, 71 (03) : 314 - 319
  • [34] DX-9065a, a specific factor Xa inhibitor, as a universal anticoagulant for blood collection tubes
    Kumura, T
    Hino, M
    Yamane, T
    Tominaga, K
    Tatsumi, N
    CLINICA CHIMICA ACTA, 2000, 294 (1-2) : 27 - 35
  • [35] Effects of a factor Xa inhibitor, DX-9065a, in a novel rabbit model of venous thrombosis
    Rogers, KL
    Chi, L
    Rapundalo, ST
    Kramer, JB
    Gallagher, KP
    BASIC RESEARCH IN CARDIOLOGY, 1999, 94 (01) : 15 - 22
  • [36] Lubeluzole pharmacokinetics in subjects with mild, moderate and severe renal impairment.
    Burstein, AH
    Lee, PID
    Gajjar, D
    Zhou, H
    Soo, Y
    Pesco-Koplowitz, L
    Hantson, L
    Woestenborghs, R
    Young, D
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 189 - 189
  • [37] THE PHARMACOKINETICS AND SAFETY OF MOMELOTINIB IN SUBJECTS WITH MODERATE OR SEVERE RENAL IMPAIRMENT.
    Xin, Y.
    Collins, H.
    Cheng, F.
    Kwan, E.
    Ramanathan, S.
    Silverman, J. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S87 - S88
  • [38] Safety and pharmacokinetics of gadobenate dimeglumine (GD) in subjects with renal impairment.
    Lambrecht, LJ
    Davies, BE
    McCloud, S
    Parker, JR
    Swan, SK
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 229 - 229
  • [39] Radioimmunoassay method for DX-9065a, an anticoagulant agent. Development, evaluation and application to human plasma
    Murayama, N
    Tanaka, S
    Kikuchi, T
    Nakaoka, M
    Sudo, K
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1996, 14 (11) : 1435 - 1445
  • [40] DX-9065a inhibition of factor Xa and the prothrombinase complex: mechanism of inhibition and comparison with therapeutic heparins
    Rezaie, AR
    THROMBOSIS AND HAEMOSTASIS, 2003, 89 (01) : 112 - 121
12345